

**In the Claims:**

This listing of claims replaces all prior versions of claims in the application:

1. (Currently amended)      A pharmaceutical dosage form suitable for oral administration comprising a molded microcellular polymeric material and a pharmaceutically acceptable active agent, and wherein the molded microcellular polymeric material is a non-thermosetting polymerized plastics material.
2. (Cancelled)
3. (Currently amended)      The pharmaceutical dosage form according to claim [[2]] 1 wherein the non-thermosetting polymerized plastics material contains at least one polyol, and at least one non-thermosetting modifier, and/or a non-thermosetting polymer.
4. (Original)    The pharmaceutical dosage form according to claim 3 wherein the non-thermosetting polymerized plastics material contains at least one polyol, and at least one non-thermosetting modifier.
5. (Original)    The pharmaceutical dosage form according to claim 3 wherein the polyol is lactitol, xylitol, sorbitol, maltitol, or mannitol, or combinations thereof.
6. (Original)    The pharmaceutical dosage form according to claim 3 wherein the non-thermosetting modifier is a starch, maltodextrin, a dextrose equivalent, polyalditol a hydrogenated starch hydrosylate, or a mixture thereof.
7. (Original)    The pharmaceutical dosage form according to claim 6 wherein the starch is pregelatinized corn starch, corn starch, potato starch, rice starch, hydroxyethyl starch, wheat starch, tapioca starch, or waxy maize starch, or mixtures thereof.

8. (Original) The pharmaceutical dosage form according to claim 6 wherein the non-thermosetting modifier is a maltodextrin.
9. (Original) The pharmaceutical dosage form according to claim 3 wherein the non-thermosetting polymer is carboxymethyl cellulose sodium, methyl cellulose, ethylcellulose, hydroxyethylcellulose (HEC), hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, noncrystalline cellulose, starch and its derivatives, and sodium starch glycolate or mixtures thereof.
10. (previously presented) The pharmaceutical dosage form according to claim 1 which optionally further comprises a sweetener, a disintegrant, a binder, a lubricant, or an opacifier.
11. (Original) The pharmaceutical dosage form according to claim 10 wherein the disintegrant is croscarmellose sodium, sodium starch glycolate, sodium carboxymethyl-cellulose, Ac-di-sol®, carboxymethyl-cellulose, veegum, an alginate, agar, guar, tragacanth, locust bean, karaya, pectin, or crospovidone.
12. (Original) The pharmaceutical dosage form according to claim 10 wherein the lubricant is glycerol monostearate, stearyl alcohol NF, stearic acid NF, Cab-O-Sil, Syloid, zinc stearate USP, magnesium stearate NF, calcium stearate NF, sodium stearate, cetostrearyl alcohol NF, sodium stearyl fumerate NF, or talc.
13. (Original) The pharmaceutical dosage form according to claim 10 wherein the opacifiers is talc USP, calcium carbonate USP, or kaolin USP.
14. (Original) The pharmaceutical dosage form according to claim 1 wherein the pharmaceutically acceptable active agent is selected from an analgesic, an anti-inflammatory agent, an anthelmintic, anti-arrhythmic, antibiotic, anticoagulant, antidepressant, antidiabetic, antiepileptic, antihistamine, antihypertensive, antimuscarinic, antimycobacterial, antineoplastic, immunosuppressant, antithyroid,

antiviral, anxiolytic and sedatives, beta-adrenoceptor blocking agents, cardiac inotropic agent, corticosteroid, cough suppressant, diuretic, dopaminergic, immunological agent, lipid regulating agent, muscle relaxant, parasympathomimetic, parathyroid, calcitonin and biphosphonates, prostaglandin, radiopharmaceutical, anti-allergic agent, sympathomimetic, thyroid agent, PDE IV inhibitor, CSBP/RK/p38 inhibitor, and a vasodilator.

15. (Original) The pharmaceutical dosage form according to claim 1 wherein the molded microcellular polymeric material is a thermoplastic polymer.

16. (Original) The pharmaceutical dosage form according to claim 15 wherein the thermoplastic polymer is polyethylene oxide, hydroxypropylcellulose, polyethylene glycol, polyvinyl pyrrolidone, copovidone, or povidone or mixtures thereof.

17. (Original) The pharmaceutical dosage form according to claim 16 wherein the polymer is polyethylene oxide, hydroxypropylcellulose, or a mixture thereof.

18. (Original) The pharmaceutical dosage form according to claim 15 which further comprises a non-thermosetting polymerized plastics material.

19. (Original) The pharmaceutical dosage form according to claim 18 wherein the non-thermosetting polymerized plastics material contains at least one polyol, and at least one non-thermosetting modifier, and/or a non-thermosetting polymer.

20. (Currently amended) The pharmaceutical dosage form according to claim 1 wherein the microcellular polymeric material is a closed cell foam.

21. (Original) A pharmaceutical dosage form comprising: a rigid microcellular foam consisting of a solid excipient having voids of substantially uniform size with a maximum void dimension in the range from about 2 to 100 microns and a void fraction in the range of about 5 to 95 percent, the solid excipient comprising a non-

thermosetting polymerized plastic material and an active pharmaceutical agent combined in a homogeneous solid mixture.

22. (Original) The pharmaceutical dosage form according to claim 21 wherein the non-thermosetting polymerized plastics material contains at least one polyol, and at least one non-thermosetting modifier, or non-thermosetting polymer.

23. (Original) The pharmaceutical dosage form according to claim 21 wherein the polyol is lactitol, xylitol, sorbitol, maltitol, or mannitol, or combinations thereof.

24. (Original) The pharmaceutical dosage form according to claim 21 wherein the non-thermosetting modifier is a starch, maltodextrin, a dextrose equivalent, polyalditol a hydrogenated starch hydrosylate, or a mixture thereof.

25. (Original) The pharmaceutical dosage form according to claim 24 wherein the starch is pregelatinized Corn Starch, Corn Starch, Potato starch, Rice starch, hydroxyethyl starch, Wheat starch, Tapioca starch, or Waxy maize starch.

26. (Original) The pharmaceutical dosage form according to claim 22 wherein the nonthermosetting modifier is a maltodextrin.

27. (Original) The pharmaceutical dosage form according to claim 21 wherein the non-thermosetting polymer is carboxymethyl cellulose sodium, methyl cellulose, ethylcellulose, hydroxyethylcellulose (HEC), hydroxypropylmethyl cellulose (HPMC), hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, noncrystalline cellulose, starch and its derivatives, and sodium starch glycolate or mixtures thereof.

28. (Currently Amended) The pharmaceutical dosage form according to claim 1 which optionally further comprises a sweetener, a disintegrant, a binder, a lubricant, or an opacifier.

29. (Original) The pharmaceutical dosage form according to claim 28 wherein the disintegrant is croscarmellose sodium, sodium starch glycolate, sodium carboxymethyl-cellulose, Ac-di-sol®, carboxymethyl-cellulose, veegum, an alginate, agar, guar, tragacanth, locust bean, karaya, pectin, or crospovidone.

30. (Original) The pharmaceutical dosage form according to claim 28 wherein the lubricant is glycerol monostearate, stearyl alcohol NF, stearic acid NF, Cab-O-Sil, Syloid, zinc stearate USP, magnesium stearate NF, calcium stearate NF, sodium stearate, cetostearyl alcohol NF, sodium stearyl fumarate NF, or talc.

31. (Original) The pharmaceutical dosage form according to claim 28 wherein the opacifiers is talc USP, calcium carbonate USP, or kaolin USP.

32. (Original) The pharmaceutical dosage form according to claim 21 wherein the active pharmaceutical agent is selected from an analgesic, an anti-inflammatory agent, an anthelmintic, anti-arrhythmic, antibiotic, anticoagulant, antidepressant, antidiabetic, antiepileptic, antihistamine, antihypertensive, antimuscarinic, antimycobacterial, antineoplastic, immunosuppressant, antithyroid, antiviral, anxiolytic and sedatives, beta-adrenoceptor blocking agents, cardiac inotropic agent, corticosteroid, cough suppressant, diuretic, dopaminergic, immunological agent, lipid regulating agent, muscle relaxant, parasympathomimetic, parathyroid, calcitonin and biphosphonates, prostaglandin, radiopharmaceutical, anti-allergic agent, sympathomimetic, thyroid agent, PDE IV inhibitor, CSBP/RK/p38 inhibitor, and a vasodilator.

33. (Original) The pharmaceutical dosage form according to claim 21 wherein the solid excipient further comprises a thermoplastic polymer.

34. (Original) The pharmaceutical dosage form according to claim 33 wherein the thermoplastic polymer is polyethylene oxide, hydroxypropylcellulose, polyethylene glycol, polyvinyl pyrrolidone, copovidone, or povidone or mixtures thereof.

35. (Original) The pharmaceutical dosage form according to claim 34 wherein the polymer is polyethylene oxide, hydroxypropylcellulose, or a mixture thereof.

36. (Original) The pharmaceutical dosage form according to claim 21 wherein the non-thermosetting polymerized plastics material contains at least one polyol, and at least one non-thermosetting modifier, and optionally a or a thermosetting polymer.

37. (Currently amended) The pharmaceutical dosage form according to claim 21 wherein the microcellular polymeric material is a closed cell foam.

38. (Original) A pharmaceutical dosage form according to claim 21, in which the homogeneous solid mixture has a sufficiently high solubility in saliva that the dosage form dissolves substantially immediately in the mouth upon oral administration.

39. (Original) A pharmaceutical dosage form according to claim 21, in which the voids are in the form of closed cells.

40. (Original) A pharmaceutical dosage form according to claim 21, in which the rigid microcellular foam is enclosed within a skin having a density substantially greater than that of the microcellular foam, but having the same composition as that of said solid mixture.

41. (Original) A pharmaceutical dosage form according to claim 21, in which the overall density of the dosage form is substantially less than that of stomach fluids, whereby the dosage form is gastro-retentive.

42. to 50. (Cancelled)